dsxtherapeutics.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | DSX |
| Description | Sepsis has very low Standard of Care in DSX Therapeutics aims to capture a significant fraction of a $19 billion per year market segment of an overall $75 billion per year sepsis treatment marke |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 50.63.92.119 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
dsxtherapeutics.com Valuation
|
US$1,005
Last updated: 2023-05-20 05:08:46
dsxtherapeutics.com has Semrush global rank of 0. dsxtherapeutics.com has an estimated worth of US$ 1,005, based on its estimated Ads revenue. dsxtherapeutics.com receives approximately 116 unique visitors each day. Its web server is located in United States, with IP address 50.63.92.119. According to SiteAdvisor, dsxtherapeutics.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$1,005 |
| Daily Ads Revenue | US$0 |
| Monthly Ads Revenue | US$27 |
| Yearly Ads Revenue | US$334 |
| Daily Unique Visitors | 7 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| dsxtherapeutics.com. | A | 600 | IP: 50.63.92.119 |
| dsxtherapeutics.com. | NS | 3600 | NS Record: ns02.domaincontrol.com. |
| dsxtherapeutics.com. | NS | 3600 | NS Record: ns01.domaincontrol.com. |
| dsxtherapeutics.com. | MX | 3600 | MX Record: 0 dsxtherapeutics-com.mail.protection.outlook.com. |
| dsxtherapeutics.com. | TXT | 3600 | TXT Record: NETORGFT10394682.onmicrosoft.com |
| dsxtherapeutics.com. | TXT | 3600 | TXT Record: v=spf1 include:secureserver.net -all |
HtmlToTextCheckTime:2023-05-20 05:08:46
| DSX Therapeutics aims to capture a significant fraction of a $19 billion per year market segment of an overall $75 billion per year sepsis treatment market based upon new enabling technologies it has discovered, developed and patented. These new technologies have led to unique new products to meet existing underserved market needs for rapid diagnostic tests and effective therapeutic treatments for sepsis and severe sepsis. The mission of DSX Therapeutics is to commercialize the first effective treatment for sepsis and severe sepsis, aSeptiMab, and the first rapid diagnostic test that is able to predict early the onset of sepsis. DSX also intends to expand its unique iNOS therapies and diagnostics into other inflammatory disorders. Sepsis has very low Standard of Care in hospitals Hospital-acquired infections (nosocomial infections) are preventable adverse patient events that affect approximately 2 million people in the USA every year and result in approximately 250,000 deaths per |
HTTP Headers
HTTP/1.1 301 Moved Permanently Content-Length: 151 Content-Type: text/html; charset=UTF-8 Location: https://dsxtherapeutics.com/ Server: Microsoft-IIS/10.0 X-Powered-By: ASP.NET X-Powered-By-Plesk: PleskWin Date: Wed, 11 Jan 2023 09:11:30 GMT HTTP/2 200 content-length: 24711 content-type: text/html last-modified: Wed, 11 Dec 2019 20:53:55 GMT accept-ranges: bytes etag: "6769ee1965b0d51:0" server: Microsoft-IIS/10.0 x-powered-by: ASP.NET x-powered-by-plesk: PleskWin date: Wed, 11 Jan 2023 09:11:31 GMT |